Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
Report summarizes monoclonal antibodies study findings from M. Watanabe and co-researchers
July 1st, 2008
According to recent research from the United States, "Vascular endothelial growth factor (VEGF) produced by tumor cells plays a central role in stimulating angiogenesis required for solid tumor growth. VEGF-specific antibodies inhibit tumor cell line growth in animal models and a humanized monoclonal anti-VEGF antibody (bevacizumab [Avastin]) is approved as a treatment for metastatic cancer." "We hypothesized that administration of an adenoviral ( Ad) vector expressing the murine monoclonal antibody equivalent of bevacizumab would suppress human tumor growth in vivo. The Ad vector (Ad alpha VEGF) encodes the light chain and heavy chain cDNAs of monoclonal antibody...
Source: Cancer Weekly (2008-07-01)
|
